Compare AstraZeneca plc (AZN) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? AstraZeneca plc trades at $168.37 (market cap $253.13B), while State Street Real Estate Select Sector SPDR ETF trades at $44.59. The key difference: AstraZeneca plc pays a 1.92% dividend while State Street Real Estate Select Sector SPDR ETF pays none, and State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | XLRE | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $45.36 |
52-Week Low | $137.44 | $40.01 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
XLRE, the Real Estate Select Sector SPDR ETF, trades at $44.70 with a 0.56% daily gain, reflecting positive momentum amid a broader real estate sector recovery. Technical indicators show a bullish moving average consensus while oscillators remain neutral. The ETF's low 0.08% expense ratio and 3.4% dividend yield provide cost-efficient real estate exposure. Recent news highlights REITs defying rate pressures with strong 2026 performance, though inflation and Treasury yield volatility remain headwinds.
The outlook for XLRE appears cautiously optimistic as real estate fundamentals improve with steady NOI growth and declining supply. Key opportunities include attractive valuations and potential rate stability, while risks center on interest rate sensitivity and economic slowdowns. With technical strength and sector tailwinds, XLRE offers diversified real estate exposure but requires monitoring of Federal Reserve policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
